

PRESS RELEASE



August 18 2017, Lund, Sweden

Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day.

The conference call, scheduled to last for a maximum of one hour, will be held in English. Following a presentation of the company by CEO Mats Grahn, we offer the opportunity to ask questions. Please call a few minutes before the conference call begins.

Date: August 23, 2017

Time: 16:00 (CET)

Phone numbers:

SE: +46 8 56642690

CH: +41 225675548

DE: +49 69222229046

DK: +45 35445575

UK: +44 2030089808

US: +1 855 8315945

On Immunovia's website under Investors/Financial Reports (<http://immunovia.com/investors/financial-reports/>) there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call.

The half-year result is expected to be published at 8:30 AM (CET) on August 23.

For questions as well as for appointment of interviews:

ir@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildecos is the company's Certified Adviser. For more information, please visit www.immunovia.com.

###